Difference between revisions of "Team:SDU-Denmark/Achievements"

Line 40: Line 40:
 
We have talked to several experts in order to develop new goals for the future perspective of our project and to expand our knowledge about the different sub elements. Among those are experts in the areas of therapeutic use of biodegradable plastic and experts in the use of antibiotics and bacteriocins as new antimicrobial components. Furthermore, we made a survey with one of the high schools we visited and used their feedback to improve the message we would like to send. We have also been talking to a nurse about what their requirements are for a patch like ours. At last we made a survey to Danish companies that work with plastic production and their possible interest in the use of plastic made by bacteria. For more information go to <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Integrated_Practices">Integrated Human Practice</a>.</li>
 
We have talked to several experts in order to develop new goals for the future perspective of our project and to expand our knowledge about the different sub elements. Among those are experts in the areas of therapeutic use of biodegradable plastic and experts in the use of antibiotics and bacteriocins as new antimicrobial components. Furthermore, we made a survey with one of the high schools we visited and used their feedback to improve the message we would like to send. We have also been talking to a nurse about what their requirements are for a patch like ours. At last we made a survey to Danish companies that work with plastic production and their possible interest in the use of plastic made by bacteria. For more information go to <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Integrated_Practices">Integrated Human Practice</a>.</li>
 
<li><b>Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry</b><br>
 
<li><b>Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry</b><br>
We have examined the <a target="blank" href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1149051">phaCAB BioBrick</a> created by imperial College’s iGEM team in 2013. We’ve characterized the relationship between the strength of the additional promoter and ribosomal binding site and the yield of plastic. In the process we’ve created another phaCAB, construct that appears to generate a higher yield of PHB. Furthermore, we’ve characterized the effect of the <a target="blank" href="http://parts.igem.org/Part:BBa_K1692020">pantothenate kinase II BioBrick</a>, submitted by imperial college’s 2015 iGEM team, on E. coli’s proteome. See our <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate">results page</a> for more information.</li>
+
We have examined the <a target="blank" href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1149051">phaCAB BioBrick</a> created by imperial College’s iGEM team in 2013. We have characterized the relationship between the strength of the additional promoter and ribosomal binding site and the yield of plastic. In the process we have created another phaCAB construct that appears to generate a higher yield of PHB. Furthermore, we have characterized the effect of the <a target="blank" href="http://parts.igem.org/Part:BBa_K1692020">pantothenate kinase II BioBrick</a> submitted by imperial college’s 2015 iGEM team on E. coli’s proteome. For more information see our <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate">results page</a> for more information.</li>
 
<li><b>Demonstrate a functional proof of concept of your project. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept</b><br>
 
<li><b>Demonstrate a functional proof of concept of your project. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept</b><br>
 
By producing bacteriocins and PHB from different BioBrick devices we have demonstrated a <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Proof">functional proof of concept</a>. Furthermore we have a BioBrick device that can secrete PHB.</li>
 
By producing bacteriocins and PHB from different BioBrick devices we have demonstrated a <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Proof">functional proof of concept</a>. Furthermore we have a BioBrick device that can secrete PHB.</li>

Revision as of 12:30, 14 October 2016

Achievements


Bronze 4/4

  • Register for iGEM, have a great summer, and attend the Giant Jamboree
    We registered and was accepted by iGEM Headquarters on 2016-05-10 09:08:56. We definitely had a great summer, and we are excited to attend at the Giant Jamboree.
  • Meet all deliverables on the Requirements page
    We sure did, you are reading our wiki right now.
    We are looking forward to attend the Giant Jamboree in Boston, where we will present our project with a talk and a poster.
    We have registered and submitted all the parts we have made.
    We filled out the safety and judging forms as the HQ asked.
  • Clearly attribute each aspect of the project
    In the section of Attributions we have described all the help we have recieved.
  • Document at least one new standard BioBrick Part or Device central to your project and submit this part to the iGEM Registry.
    K2018030 is a secretion system for poly-beta-hydroxybutyrate (PHB). This secretion tags PHB with a hybrid protein consisting of phasin, a protein that binds PHB and a hemolysin tag, that is recognised by a type 2 secretion system. The BioBrick also contains two transport proteins that will recognize the hybrid protein and secrete it along with the PHB. This construct generates an enormous increase in PHB yield and creates the possibility for a large scale continous production of PHB in a fed batch.

Silver 3/3

  • Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected
    Our new devices K2018014 and K2018015 which are hybrid bacteriocins, have shown great effect at inhibiting growth of multi resistant Staphylococcus aureus and Pseudomonas aeruginosa. The hybrids showed greater effect than a single bacteriocin's proteins. This suggests that the two bacteriocins in the hybrid have a synergistic effect.
  • Collaboration
    We have helped these iGEM teams in different ways: The iGEM team from the Technical University of Denmark, the iGEM team from Copenhagen University, the iGEM team from Chalmers University of Technology, the iGEM team from Stockholm, the iGEM team from Virginia and the iGEM team from LMU TUM munich. For more details see Collaborations.
  • Human practice
    We have presented our project at different events were we also have discussed synthetic biology. We have done some work on bioethics and philosophy of science, which have been a big part of our considerations about methods and the project. For more details see Practices and Prospects.

Gold 4/4

  • Integrated human practice; Expand on your silver medal activity of human practice by demonstrating how you have integrated the investigated issues into the design and/or execution of your project
    We have talked to several experts in order to develop new goals for the future perspective of our project and to expand our knowledge about the different sub elements. Among those are experts in the areas of therapeutic use of biodegradable plastic and experts in the use of antibiotics and bacteriocins as new antimicrobial components. Furthermore, we made a survey with one of the high schools we visited and used their feedback to improve the message we would like to send. We have also been talking to a nurse about what their requirements are for a patch like ours. At last we made a survey to Danish companies that work with plastic production and their possible interest in the use of plastic made by bacteria. For more information go to Integrated Human Practice.
  • Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry
    We have examined the phaCAB BioBrick created by imperial College’s iGEM team in 2013. We have characterized the relationship between the strength of the additional promoter and ribosomal binding site and the yield of plastic. In the process we have created another phaCAB construct that appears to generate a higher yield of PHB. Furthermore, we have characterized the effect of the pantothenate kinase II BioBrick submitted by imperial college’s 2015 iGEM team on E. coli’s proteome. For more information see our results page for more information.
  • Demonstrate a functional proof of concept of your project. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept
    By producing bacteriocins and PHB from different BioBrick devices we have demonstrated a functional proof of concept. Furthermore we have a BioBrick device that can secrete PHB.
  • Show your project working under real-world conditions. To achieve this criterion, you should demonstrate your whole system, or a functional proof of concept working under simulated conditions in the lab
    By making MIC’s with our bacteriocins in the laboratory, we have shown that they work against different human pathogens, and they can therefore be used in real-world conditions. We have increased the production of PHB by implementing a secretion system. By 3D printing actual products by our produced PHB, we have demonstrated our whole systems works under real-world conditions. Furthermore we have been coding with our PHB with the intention of using coated bacteriocins for drug delivery. To see more go to Demonstration & Results and Proof of Concept.